|Project Title||Principal Investigator||Institution|
|Biomarkers for autism and for gastrointestinal and sleep problems in autism||Anderson, George||Yale University|
|ACE Center: Gaze perception abnormalities in infants with ASD||Chawarska, Katarzyna||Yale University|
|Prospective study of infants at high risk for autism||Chawarska, Katarzyna||Yale University|
|Model diagnostic lab for infants at risk for autism||Klin, Ami||Yale University|
|Brain-behavior growth charts of altered social engagement in ASD infants||Klin, Ami||Yale University|
|Physical and clinical infrastructure for research on infants-at-risk for autism at Yale||Klin, Ami||Yale University|
|ACE Center: Assessment Core||Klin, Ami||Yale University|
|The ontogeny of social visual engagement in infants at risk for autism||Klin, Ami||Yale University|
|Misregulation of BDNF in autism spectrum disorders||Hempstead, Barbara||Weill Cornell Medical College|
|Developmental characteristics of MRI diffusion tensor pathway changes in autism||Conturo, Thomas||Washington University|
|Observational and electrophysiological assessments of temperament in infants at risk for autism spectrum disorders||Burner, Karen||University of Washington|
|A longitudinal 3-D MRSI study of infants at high risk for autism||Dager, Stephen||University of Washington|
|Neurophysiological indices of risk and outcome in autism||Webb, Sara||University of Washington|
|ACE Center: Linguistic and social responses to speech in infants at risk for autism||Kuhl, Patricia||University of Washington|
|Early social and emotional development in toddlers at genetic risk for autism||Campbell, Susan||University of Pittsburgh|
|Defining high and low risk expression of emotion in infants at risk for autism||Hannigen, Sarah||University of Pittsburgh|
|Early identification of autism: A prospective study||Iverson, Jana||University of Pittsburgh|
|Temporal coordination of social communicative behaviors in infant siblings of children with autism||Parlade, Meaghan||University of Pittsburgh|
|Supplement to NIH ACE Network grant: "A longitudinal MRI study of infants at risk for autism"||Piven, Joseph||University of North Carolina at Chapel Hill|
|ACE Network: A longitudinal MRI study of infants at risk for autism||Piven, Joseph||University of North Carolina at Chapel Hill|
|Validation study of atypical dynamic pupillary light reflex as a biomarker for autism||Yao, Gang; Miles, Judith; Christ, Shawn||University of Missouri|
|The emergence of emotion regulation in children at-risk for autism spectrum disorder||Ekas, Naomi||University of Miami|
|Pupil size and circadian salivary variations in autism spectrum disorder||Colombo, John||University of Kansas|
|Abnormal vestibulo-ocular reflexes in autism: A potential endophenotype||White, Keith||University of Florida|
|ACE Center: MRI studies of early brain development in autism||Courchesne, Eric||University of California, San Diego|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.